Camp4 Therapeutics (CAMP) Director Michael MacLean Receives Award

What Happened

• Michael F. MacLean, a director of Camp4 Therapeutics (CAMP), received a derivative award covering 56,000 shares on 2026-04-01. The report lists the per-share acquisition price as $0.00 and the immediate reported value as $0 — this is a grant of compensation, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (timely).
• Securities: 56,000 derivative shares granted; reported price $0.00 per share; reported value $0.
• Vesting: Shares underlying the option vest in equal monthly installments over three years commencing from the grant date (footnote F1).
• Shares owned after transaction: Not disclosed in this filing.
• Filing status: Timely (no late filing indicated).

Context

• This was a compensation grant (derivative award/options) rather than a market buy or sale, so it reflects company compensation policy rather than an immediate trading signal. The award vests monthly over three years, meaning the economic interest is earned over time rather than immediately.